Synthetic Biology Inspired Medicines
We design and engineer microbial strains rationally to manufacture or as medicines for infectious diseases, cancer and beyond
Discover more
Delonix is a world leading biotech company dedicated to design and engineering of microbes for medicines.
Founded by experts in synthetic biology, vaccinology and cancer immunotherapies, Delonix holds the ambition to reform the way we develop and manufacture medicines for challenging health issues.
What We Are Doing
Accelerated
manufacture of medicines
Inspired by nature, adjuvant molecules, polysaccharide protein conjugates, diverse antigens and even RNA can be designed and biosynthesized efficiently within a cell, or in a cell-free way, driving process simplification.
Synthetic
live vaccine
Live vaccine is among the most effective vaccine types against untackled bacterial infections. We apply rational design to engineer vaccine strains, enabling serotype-independent protection.
Synthetic
cancer therapies
Like oncolytic virus, bacteria harness the power of tumor cell lysis and immune stimulation. Bacteria can be further engineered to target solid tumors and deliver all kinds of therapeutic payloads, precisely and continuously.
01
Synthetic Biology
Platform
  • Complete toolkits for non-model microbe engineering
  • Data-driven rational design
  • High throughput & automation


02
Vaccine Technology
Platform
  • Surfomics and reverse vaccinology for efficient antigen discovery
  • Immune checkpoints for vaccine development
  • Various in vivo infection models


What's happening about us?
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021
  • Delonix Bioworks Closes $14 Million Series Seed Financingto Accelerate the Development of its Innovative Synthetic Vaccines
    Oct 10, 2021
  • $14 Million Series Seed Financingto Accelerate the Development of its Innovative Synthetic Vaccines
    Oct 10, 2021
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021
  • Delonix Bioworks Wins Boehringer Ingelheim’s Innovation Prize in 2020
    Oct 10, 2021